Treatment of chronic hepatitis C (HCV) is currently undergoing a significant change.
Traditional interferon-based therapy has been limited by both efficacy and tolerability, and …

Direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) proteins open a whole
new era for anti-HCV therapy, but DAA resistance associated variants (RAVs) could …

Background & Aims Ledipasvir/sofosbuvir combination treatment in phase III clinical trials
resulted in sustained viral suppression in 94–99% of patients. This study characterized drug …

There has been a remarkable transformation in the treatment of chronic hepatitis C in recent
years with the development of direct acting antiviral agents targeting virus encoded proteins …

Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus
(HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused …

Neither an animal model nor a cell culture system has been established for the genotype 5
hepatitis E virus (G5 HEV), and the pathogenicity, epidemiology, and replication mechanism …

The development of new models and tools has led to the discovery and clinical development
of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals …

Chikungunya virus (CHIKV) is the causative agent of chikungunya fever (CHIKF) and is
categorized as a (n)(re) emerging arbovirus. CHIKV has repeatedly been responsible for …

Background & Aims Direct-acting antivirals (DAAs) effectively eradicate chronic hepatitis C
virus (HCV) infection, although HCV genotype 3a is less responsive to these drugs. We …

Background. Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B
substitution or phenotypic resistance detected in phase 3 registration studies. Methods …